MedTrace Logo

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis

NCT00245622 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2014-03-10

No results posted yet for this study

Summary

This is a 1 year study to evaluate the efficacy, safety, and tolerability of Tovaxin T cell therapy in subjects with a clinically isolated syndrome (CIS) and relapse-remitting multiple sclerosis (RR-MS).

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

BIOLOGICAL

Tovaxin Autologous T cell vaccine

subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24

BIOLOGICAL

Placebo

subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24

Sponsors & Collaborators

  • Opexa Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Edward J Fox, M.D., Ph.D. · Central Texas Neurology Consultants

  • Jaye Thompson, Ph.D. · Opexa Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245622 on ClinicalTrials.gov